Ofloxacin is an antimicrobial drug in the fluoroquinolone family that effectively treats various bacterial infections. It received FDA approval in 1990 as a "1C" drug, categorizing it as a new molecular entity offering little or no therapeutic advantage over existing therapies, namely, ciprofloxacin. Yet, despite its little therapeutic benefit, ofloxacin earned support for its improved oral bioavailability, longer half-life, and expanded applications to certain sexually transmitted infections compared to its counterpart, ciprofloxacin.****Pseudomonas aeruginosa may develop resistance rapidly during treatment with ofloxacin. Hence, Culture and susceptibility testing performed during therapy can provide information about the therapeutic effect of the antimicrobial agent and the possible emergence of bacterial resistance. Fluoroquinolones, including ofloxacin, are associated with serious adverse reactions; hence it is prudent to reserve ofloxacin where there are no alternative treatment options.

The following are FDA-approved indications for ofloxacin use according to the manufacturer label.

- Otitis Externa in pediatric patients six months and older and adults from infection with Escherichia coli, Pseudomonas aeruginosa, or Staphylococcus aureus (otic solution, 0.3%)

- Chronic Suppurative Otitis Media in patients 12 years and above with perforated tympanic membranes because of Pseudomonas aeruginosa, Proteus mirabilis, or Staphylococcus aureus (otic solution, 0.3%)

- Acute Otitis Media in pediatric patients one year age with tympanostomy tubes due to Moraxella catarrhalis, Haemophilus influenzae, Pseudomonas aeruginosa Staphylococcus aureus, or Streptococcus pneumonia (otic solution, 0.3%)

- Conjunctivitis due to Enterobacter cloacae, Staphylococcus aureus, Staphylococcus epidermidis, Haemophilus influenzae, Streptococcus pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa (ophthalmic solution 0.3%)

- Corneal ulcers due to infection with Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, or Cutibacterium acnes. (ophthalmic solution 0.3%)

- Acute bacterial exacerbations of chronic bronchitis resulting from Haemophilus influenzae or Streptococcus pneumoniae

- Community-acquired pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae

- Uncomplicated skin and skin structure infection due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis

- Acute, uncomplicated urethral and cervical gonorrhea from Neisseria gonorrhoeae infection

- Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis

- Mixed infections of the urethra and cervix with Chlamydia trachomatis or Neisseria gonorrhoeae

- Acute pelvic inflammatory disease (includes severe infection) due to Chlamydia trachomatis or Neisseria gonorrhoeae

- Uncomplicated cystitis as a result of Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa

- Complicated urinary tract infections from infection with Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, or Pseudomonas aeruginosa

- Prostatitis resulting from Escherichia coli

The following are the non-FDA-approved use of ofloxacin.

- Leprosy

- Epididymitis

- Spontaneous bacterial peritonitis

- Traveler's diarrhea(TD)- According to the American Society for Microbiology, fluoroquinolones should no longer be considered the drugs of choice for the prevention or treatment of TD for travelers traveling to India and Africa due to the emergence of resistance to Fluoroquinolones.

- Enteric fever- Fluoroquinolones are used for empiric treatment of enteric fever in adults and are regarded as the treatment of choice for fluoroquinolone-susceptible infections. However, in the United States, ≥90% of Typhi and Paratyphi A infections in travelers to South Asia are fluoroquinolone-nonsusceptible, suggesting that treatment failures may occur among patients treated empirically with fluoroquinolones. Hence, azithromycin and ceftriaxone are increasingly used to treat enteric fever.